---- ----
Revenues:
Net sales $9,914 $4,046 $17,105 $16,799
Royalties 375,400 2,028 375,400 2,028
Licensing fees 766,281 266,282 1,032,562 532,563
Consulting fees 70,000 162,000 140,000 284,185
------ ------- ------- -------
Total Revenues 1,221,595 434,356 1,565,067 835,575
Costs and expenses:
Research and
development 124,192 94,432 240,063 188,703
General and
administrative 1,140,485 1,173,316 2,307,456 1,973,772
--------- --------- --------- ---------
Total Cost and
Expenses 1,264,677 1,267,748 2,547,519 2,162,475
--------- --------- --------- ---------
Operating loss (43,082) (833,392) (982,452) (1,326,900)
Other income (expense):
Interest income 1,688 27,528 4,545 57,803
Interest expense (39) - (39) (451)
Other, net - 4,527 (9,463) 4,527
----- ----- ------ -----
1,649 32,055 (4,957) 61,879
----- ------ ------ ------
Loss before benefit
(expense) for income
tax (41,433) (801,337) (987,409) (1,265,021)
Income tax benefit
(expense) (46,376) - (46,376) -
------- ------- ------- ---------
Net loss $(87,809) $(801,337) $(1,033,785) $(1,265,021)
======== =========
'/>"/>SOURCE BioSpecifics Technologies Corp. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC2.
BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering3.
BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan4.
BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering5.
BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering6.
BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results7.
BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease8.
BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors9.
BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference10.
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market11.
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results